Related Experiment Video
Updated: May 20, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Vassilios S Ramfidis1, Alexios S Strimpakos, Kostas N Syrigos
1Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece.
Abstract:
Despite the enormous advances in clinical research in oncology, the prognosis of pancreatic carcinoma remains poor. The therapeutic options in this type of cancer are very limited, with modest results at present. In the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, four interesting trials on the second line treatment of pancreatic cancer were presented. The first study (Abstract #4017) with a phase II design suggested that maintenance therapy with sunitinib, after a complete course of standard first line treatment, was feasible and effective while the second phase I/II study (Abstract #4034) evaluated the role of trabedersen, an agent that inhibits TGF-β2 expression. Finally, the efficacy and toxicity of lapatinib combined with either FOLFOX (Abstract #e14533) or capecitabine (Abstract #e14569) were examined in the second line setting of pancreatic cancer.
Insights
New pancreatic cancer treatments show promise. Sunitinib maintenance therapy and novel agents like trabedersen, lapatinib with FOLFOX, or capecitabine are being explored for improved patient outcomes in second-line treatment settings.
Area of Science:
- Oncology
- Clinical Research
- Gastroenterology
Background:
- Pancreatic carcinoma has a poor prognosis despite advances in oncology.
- Current therapeutic options for pancreatic cancer are limited with modest efficacy.
Purpose of the Study:
- To present promising second-line treatment strategies for pancreatic cancer from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Main Methods:
- Phase II trial of sunitinib maintenance therapy post-first-line treatment.
- Phase I/II trial evaluating trabedersen, a TGF-β2 inhibitor.
- Examination of lapatinib efficacy and toxicity combined with FOLFOX or capecitabine.
Main Results:
- Sunitinib maintenance therapy demonstrated feasibility and effectiveness.
- Trabedersen's role in inhibiting TGF-β2 was evaluated.
- Efficacy and toxicity profiles of lapatinib plus FOLFOX/capecitabine were assessed.
Conclusions:
- Investigational therapies including sunitinib, trabedersen, and lapatinib combinations offer potential advancements in second-line pancreatic cancer treatment.
- Further research is warranted to optimize these strategies for better patient outcomes.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers